Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A1BG antisense RNA 1 (A1BG-AS1)
- Target
- A1BG-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA
01
Overview
A1BG antisense RNA 1 (A1BG-AS1) is a long non-coding RNA encoded on chromosome 19, functioning primarily as a regulatory molecule in cellular gene expression. In hepatocellular carcinoma, it acts as a tumor suppressor by sponging miR-216a-5p, thereby upregulating tumor suppressor genes such as PTEN and SMAD7[2][3][7]. In breast cancer, A1BG-AS1 promotes proliferation, migration, invasion, and chemotherapy resistance by stabilizing ABCB1 (MDR1) mRNA via interaction with IGF2BP2, impacting adriamycin resistance[4]. It has also been linked to immune regulation by influencing key immune response genes[5]. While it is not the direct target of approved drugs, its expression serves as a prognostic biomarker in several cancers and suggests potential as a future therapeutic target or biomarker in oncology and immunology.
- Other names
- NCRNA00181FLJ23569A1BG-ASA1BGASA1BG antisense RNA (non-protein coding)A1BG antisense RNA 1 (non-protein coding)
02
Mechanism of action
Not applicable; serves as a regulatory RNA affecting gene networks rather than being directly targeted pharmacologically
03
Biological functions
Regulation of gene expression via ceRNA (competing endogenous RNA) mechanismsInhibition of cancer cell proliferation, migration, and invasion (tumor suppressor function in hepatocellular carcinoma)Promotion of chemotherapy resistance in breast cancer (adriamycin resistance)Regulation of immune response by affecting expression of immune-related genes (e.g., CD40, ELF4, NLRP1, MR1, TMEM173)
04
Disease associations
Cancer (especially hepatocellular carcinoma and breast cancer)Chemotherapy resistance in breast cancerImmune-related diseases (potential, based on regulation of immune gene networks)
05
Safety considerations
None directly known for A1BG-AS1 as a molecule; safety concerns would relate to therapeutic modulation of lncRNAs generally, such as off-target effects and delivery challenges
06
Biomarkers
Prognostic biomarker for recurrence-free survival in breast cancerIndicator of adverse clinical features and outcomes in hepatocellular carcinomaExpression level biomarker for chemotherapy resistance in breast cancer
Beyond the preview
Go deeper on A1BG antisense RNA 1 (A1BG-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A1BG antisense RNA 1 (A1BG-AS1).